End-of-Surgery Remimazolam Trial Measured Agitation During Early Recovery

A small placebo-controlled trial found less immediate agitation, while leaving later behavior and rare complications uncertain.

What the supplied paper reports

Sixty-two adults undergoing rhinologic surgery with sevoflurane received remimazolam or saline near the end of anesthesia. Agitation at extubation occurred in twelve of thirty-two controls and none of thirty remimazolam recipients. Extubation times were similar. The trial used repeated agitation assessments during the first thirty minutes in recovery.

What the findings cannot establish

Participants were selected adults with relatively low anesthetic risk. The single-center sample was too small to characterize uncommon complications, and the agitation assessment window did not establish later behavioral outcomes. The study did not compare alternative preventive drugs or determine a dose-response relationship.

Implications for forensic review

For a recovery-room event, identify the assessment scale and exact observation period. No observed agitation in thirty treated patients is a sample result, not a guarantee of prevention. The finding concerns a bolus during emergence and should not be merged indiscriminately with studies replacing an entire anesthetic regimen.

Source and related reading

Source reviewed: Remimazolam Bolus Prevents Emergence Agitation After Rhinologic Surgery A Randomized Triple Blind Co (PMC13027865). The forensic applications above are interpretive analysis of the supplied paper.